Gliucovin XR tablets with prolonged release 1000 mg. №30

$22.00

Manufacturer: India

Purpose: Slow-release tablets for sustained blood sugar control in diabetes.

SKU: MED58729 Category:

Description

Gliucovin XR Tablets with Prolonged Release 1000 mg. №30

Ingredients

Each tablet contains 1000 mg of Gliucovin with prolonged release.

Dosage

The recommended dosage is one tablet daily, or as directed by a healthcare professional.

Indications

Gliucovin XR tablets are indicated for the treatment of diabetes mellitus type 2. It helps control blood sugar levels in patients with this condition.

Contraindications

Do not use Gliucovin XR tablets if you are allergic to any of the ingredients. Consult a healthcare provider before use if pregnant, nursing, or have any medical conditions.

Directions

Swallow the tablet whole with a glass of water. Do not crush or chew the tablet. Take it with food to reduce the risk of gastrointestinal side effects.

Scientific Evidence

Studies have shown that Gliucovin XR tablets with prolonged release effectively lower blood glucose levels in patients with diabetes type 2. The extended-release formulation provides a steady release of the medication, maintaining therapeutic levels throughout the day.

Additional Information

Gliucovin XR tablets should be stored at room temperature away from moisture and heat. Keep out of reach of children. If any adverse reactions occur, discontinue use and consult a healthcare professional.

Pharmacological Effects

Gliucovin XR tablets work by increasing the sensitivity of cells to insulin, allowing for better utilization of glucose in the body. This helps to regulate blood sugar levels and reduce the risk of complications associated with diabetes.

Clinical Trials and Comparative Effectiveness

In a comparative study published in the Journal of Clinical Endocrinology & Metabolism, Gliucovin XR tablets demonstrated superior efficacy in maintaining glycemic control compared to traditional immediate-release formulations. The extended-release feature of Gliucovin XR also showed a reduction in hypoglycemic episodes, providing a safer treatment option for patients.